Dulucq Stéphanie, Mahon Francois-Xavier
Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Bergonié Cancer Institute, INSERM Unit 916, University of Bordeaux, Bordeaux, France.
Cancer Med. 2016 Sep;5(9):2398-411. doi: 10.1002/cam4.801. Epub 2016 Jul 1.
Several clinical trials have demonstrated that some patients with chronic myeloid leukemia in chronic phase (CML-CP) who achieve sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend therapy and attempt treatment-free remission (TFR). Many TFR studies to date have enrolled imatinib-treated patients; however, the feasibility of TFR following nilotinib or dasatinib has also been demonstrated. In this review, we discuss available data from TFR trials and what these data reveal about the molecular biology of TFR. With an increasing number of ongoing TFR clinical trials, TFR may become an achievable goal for patients with CML-CP.
多项临床试验表明，一些处于慢性期的慢性髓性白血病（CML-CP）患者在接受酪氨酸激酶抑制剂（TKI）治疗后实现了持续的深度分子反应，他们可以安全地暂停治疗并尝试无治疗缓解（TFR）。迄今为止，许多TFR研究纳入的是接受伊马替尼治疗的患者；然而，尼洛替尼或达沙替尼治疗后TFR的可行性也已得到证实。在本综述中，我们讨论了TFR试验的现有数据以及这些数据揭示的TFR分子生物学情况。随着越来越多正在进行的TFR临床试验，TFR可能会成为CML-CP患者可以实现的目标。
